Evaluating the Effectiveness and Acceptability of a GPT-4o and RAG-Based Voice Chatbot for Depression Screening Using PHQ-9
Launched by UNIVERSITY COLLEGE, LONDON · Jan 24, 2025
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Depression is a prevalent mental health challenge with significant personal, social, and economic costs. Traditional mental health resources face barriers such as stigma, limited availability, and long wait times. Technology, particularly AI-powered tools, provides an opportunity to bridge these gaps. This study utilizes GPT-4o and RAG to create a voice-interactive chatbot capable of conversational engagement, administering the PHQ-9 questionnaire, and delivering personalized feedback.
Participants will fill in the PHQ-9 for self-testing before interacting with the chatbot (the results wil...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults aged 18-65 years.
- • Fluent in English.
- • Access to a device capable of voice interaction and stable internet connection.
- • Willing to participate in chatbot interaction and a follow-up interview.
- Exclusion Criteria:
- • Current severe psychiatric diagnoses (e.g., psychosis, bipolar disorder).
- • Participants undergoing active treatment for depression with a psychiatrist.
- • Discomfort with voice-based technology or inability to provide informed consent.
About University College, London
University College London (UCL) is a leading global research institution renowned for its commitment to advancing healthcare through innovative clinical trials. As a prominent sponsor of clinical research, UCL leverages its multidisciplinary expertise and state-of-the-art facilities to conduct rigorous investigations aimed at improving patient outcomes and addressing pressing medical challenges. The institution fosters collaboration among researchers, healthcare professionals, and industry partners, ensuring that its trials adhere to the highest ethical standards and regulatory guidelines. UCL's dedication to translating scientific discoveries into practical applications underscores its role as a vital contributor to the advancement of medical science and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, , United Kingdom
Patients applied
Trial Officials
Kezhi Li
Study Director
University College, London
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported